Stay updated on Efficacy Safety Rituximab + Omalizumab Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Rituximab + Omalizumab Clinical Trial page.
Latest updates to the Efficacy Safety Rituximab + Omalizumab Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedLocations now include California under Locations. The California Locations entry and HHS Vulnerability Disclosure link were removed, and the page revision updated to v3.3.3.SummaryDifference0.2%
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.3.2 replacing v3.3.1. No visible changes to study content are indicated.SummaryDifference0.1%
- Check38 days agoChange DetectedRevision: v3.3.1 replaces the previous v3.2.0 on the page. No changes to study details, eligibility, or outcome measures are evident.SummaryDifference0.1%
- Check46 days agoChange DetectedThe site removed the government funding status notice that used to appear on this page, and the core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check60 days agoChange DetectedNo additions or deletions were detected; the page content appears unchanged.SummaryDifference0.5%
- Check89 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference4%
Stay in the know with updates to Efficacy Safety Rituximab + Omalizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Rituximab + Omalizumab Clinical Trial page.